Article
Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation.
Oncogene - 7 May 1998
Houldsworth J, Xiao H, Murty V V, Chen W, Ray B, Reuter V E, Bosl G J, Chaganti R S
Abstract excerpt
Male germ cell tumors (GCTs) are uniquely sensitive to cisplatin-based chemotherapy, with more than 90% of newly diagnosed cases cured. The underlying cause for resistance to treatment in 20-30% of metastatic lesions remains to be identified. Unlike other solid tumors, no mutations in the TP53 gene have been identified to date in random panels of GCT specimens, which could account for the exquisite sensitivity of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.